Stay updated on Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial

Sign up to get notified when there's something new on the Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    No additions or deletions were detected on the page; the content appears unchanged between versions.
    Difference
    0.4%
    Check dated 2025-11-03T21:24:33.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    39 days ago
    Change Detected
    Summary
    Major update: operating-status notice and new version v3.2.0; old v3.1.0 reference removed.
    Difference
    4%
    Check dated 2025-10-06T05:52:13.000Z thumbnail image
  5. Check
    46 days ago
    Change Detected
    Summary
    Version updated from v3.0.2 to v3.1.0; no other content changes detected.
    Difference
    0.1%
    Check dated 2025-09-29T03:10:23.000Z thumbnail image
  6. Check
    60 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.0.2, replacing v3.0.1. The 'Back to Top' link was removed.
    Difference
    0.2%
    Check dated 2025-09-14T19:18:41.000Z thumbnail image
  7. Check
    67 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content, pricing, or availability.
    Difference
    0.2%
    Check dated 2025-09-07T15:58:35.000Z thumbnail image
  8. Check
    75 days ago
    Change Detected
    Summary
    The web page has undergone significant updates, including the addition of specific facility names and locations, as well as the introduction of new medical terms such as Hyaluronidase and ocrelizumab. The revision number has also changed from v2.16.12 to v3.0.0.
    Difference
    2%
    Check dated 2025-08-31T11:55:39.000Z thumbnail image

Stay in the know with updates to Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial page.